IDENTIFICATION OF POTENTIAL DRUG-RELATED PROBLEMS (DRPS) AT PREECLAMPSIA AND ECLAMPSIA PATIENTS AT RSUP DR. HASAN SADIKIN BANDUNG

• Main Author: Olpah Siara, Fathiah
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/76386
• Institution: Institut Teknologi Bandung

Preeclampsia and eclampsia are syndromes in pregnancy that cause morbidity and mortality therefore the appropriateness of therapy is needed. The high incidence of Drug Related Problems (DRPs) or drug-related problems can affect the unsuccess of therapy so this research needs to be done. The purpose of the study was to identify and assess the incidence of potential drug-related problemsin preeclampsia and eclampsia patients with or without comorbid diseases. The research conducted was a descriptive nonexperimental study with a cross-sectional design conducted retrospectively from medical record data during the period January - December 2021. Sampling was carried out using a non-probability sampling method, namely purposive sampling, with a total sample of 134 patients. The inclusion criteria of subjects are hospitalized patients with a diagnosis of preeclampsia and eclampsia with or without comorbid diseases, while the exclusion criteria are patients with incomplete or illegible medical records. Results of potential DRPs showed as many as 36 cases (8.71%) of P.1 code of treatment effectiveness for untreated symptoms or indications (P1.3). 109 cases (26.39%) code C.1 drug selection for no drug indication (C1.3). 109 cases (26.39%) code C1.4 drug interactions. 101 cases (24.45%) polypharmacy of code C1.7. 36 cases (8.71%) code C1.6 indicated untreated. 5 cases (1.21%) of drug code C1.1 do not match the guidelines. 2 cases (0.48%) of the drug code C1.2 according to the guidelines but there are contraindications. 2 cases (0.48%) code C1.5 duplication of the drug. 8 cases (1.93%) code C.3 dose selection for excess drug dosage (C3.2). 5 cases (1,21%) code C3.1 dose of subtherapeutic drugs. The results of bivariate analysis showed that age, gestational age, gestational status, diagnosis, disease diagnosis, number of diagnoses, number of drugs, and length of stay significantly increased the incidence of DRPs in patients (p < 0.05) and the results of multivariate analysis using logistic regression showed a significant difference in increasing the incidence of DRPs in patients with Omnibus Test (P) results (p < 0.05). Results of potential DRPs showed 86 cases (3.53%) of magnesium sulfate with drug interactions and 185 (22.07%) uses in therapy.